Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer

Eur J Cancer Clin Oncol. 1987 May;23(5):517-20. doi: 10.1016/0277-5379(87)90313-0.


Tamoxifen, an antiestrogen which competes for the estrogen receptor, modulates natural killer cell activity in vivo. Seventeen post-menopausal stage I breast cancer patients received tamoxifen for 1 month and a statistically significant increase in NK activity was demonstrated (P = 0.0005). There was a small incremental shift in the number of Leu-11b positive cells. These data demonstrate that tamoxifen functions as a biological response modifier.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Killer Cells, Natural / drug effects*
  • Menopause
  • Middle Aged
  • Neoplasm Staging
  • Phenotype
  • Tamoxifen / therapeutic use*


  • Tamoxifen